26 Mar 2014 07:00
Notice of Results
LONDON, UK, 26 March, 2014 - Skyepharma PLC (LSE SKP), the expert oral and inhalation drug delivery company, will announce its annual financial results for the year ended 31 December 2013 on Monday 31 March 2014. The results presentation and a webcast recording of the event will be available on the Company's website at www.skyepharma.com.
-Ends-
For further information please contact:
Skyepharma PLC | |
Peter Grant, Chief Executive Officer | +44 207 881 0524 |
Andrew Derodra, Chief Financial Officer
| |
FTI Consulting | |
Julia Phillips/Stephanie Cuthbert/Natalie Garland-Collins | +44 203 727 1000 |
N+1 Singer | |
Shaun Dobson/Gillian Martin | +44 207 496 3000 |
About Skyepharma
Skyepharma combines proven scientific expertise with validated proprietary drug delivery technologies to develop innovative oral and inhalation pharmaceutical products. The Group is eligible for revenues from 15 approved products in the areas of inhalation, oral, topical and injectable drug delivery as well as generating income from the development of further products and technology licenses. The products developed by the Group are marketed throughout the world by big pharma as well as specialty pharmaceutical companies. For more information, visit www.skyepharma.com.